JOINT APPLICATION OF BRAIN MRI AND GENE EXPRESSION ATLAS TO RECONSTRUCT NMOSD PATHOPHYSIOLOGY

Objective. Brain lesions in aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) occur at areas of high AQP4 expression. However, the pathophysiological cascade requires additional factors such as complement. We sought to investigate the spatial association between brain damage and gene expression in AQP4+NMOSD. Methods. In this multicenter cross-sectional study, we enrolled 90 patients and 94 age-matched healthy controls who underwent a 3.0/1.5 T brain MRI. In patients, brain damage was assessed through (i) T2-hyperintense lesion probability maps, (ii) white matter (WM) and grey matter (GM) atrophy on 3D T1-weighted sequences, and (iii) WM microstructural abnormalities on diffusion-tensor imaging. The association between imaging maps and the expression of 266 candidate genes in the Allen Human Brain Atlas was obtained and overrepresented biological processes were investigated with a functional-enrichment analysis. Results. In AQP4+NMOSD, T2-hyperintense lesions were mainly located in the periventricular WM. GM and WM atrophy involved the visual pathway, while WM microstructural abnormalities were represented by a widespread increase of mean diffusivity. The expression of AQP4, C4a and C5 elements of complement resulted associated with all types of brain damage. Complement activation and the regulation and uptake of insulin-like growth factor were the most relevant enriched pathways. Non-specific pathways related to DNA synthesis and repair were associated with brain atrophy. Interpretation. A joint application of quantitative MRI and gene expression atlas can identify in vivo the key elements of AQP4+NMOSD pathophysiology. This may pave the way to a novel type of imaging analysis helpful in understanding the pathophysiology of antibody-mediated autoimmune disorders.

[1]  C. Pozzilli,et al.  Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (S5.003) , 2023, Sunday, April 23.

[2]  C. Lucchinetti,et al.  Investigating the Immunopathogenic Mechanisms Underlying MOGAD , 2021, Annals of neurology.

[3]  J. Lünemann,et al.  Reply to “Investigating the Immunopathogenic Mechanisms Underlying MOGAD” , 2021, Annals of neurology.

[4]  Gary D Bader,et al.  The reactome pathway knowledgebase 2022 , 2021, Nucleic Acids Res..

[5]  J. Lünemann,et al.  Complement Activation Is a Prominent Feature of MOGAD , 2021, Annals of neurology.

[6]  M. Levy,et al.  B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20 , 2021, ImmunoTargets and therapy.

[7]  B. Weinshenker,et al.  Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders , 2021, Neurology.

[8]  E. McDonagh,et al.  Open Targets Platform: supporting systematic drug–target identification and prioritisation , 2020, Nucleic Acids Res..

[9]  You-Wen He,et al.  A Potential Role of Interleukin 10 in COVID-19 Pathogenesis , 2020, Trends in Immunology.

[10]  K. Fujihara,et al.  Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[11]  M. Filippi,et al.  Mapping white matter damage distribution in neuromyelitis optica spectrum disorders with a multimodal MRI approach , 2020, Multiple sclerosis.

[12]  N. Ashpole,et al.  Loss of insulin‐like growth factor‐1 signaling in astrocytes disrupts glutamate handling , 2019, Journal of neurochemistry.

[13]  Mhs,et al.  Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder , 2019 .

[14]  J. Vilo,et al.  g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update) , 2019, Nucleic Acids Res..

[15]  Ben D. Fulcher,et al.  A practical guide to linking brain-wide gene expression and neuroimaging data , 2018, NeuroImage.

[16]  K. Bhatia,et al.  Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology , 2017, Brain : a journal of neurology.

[17]  Yeseul Kim,et al.  Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder , 2017, Journal of Neuroinflammation.

[18]  Hui Zhang,et al.  Towards a comprehensive framework for movement and distortion correction of diffusion MR images: Within volume movement , 2017, NeuroImage.

[19]  Alex Rovira,et al.  Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach , 2017, NeuroImage.

[20]  P. Expert,et al.  MENGA: A New Comprehensive Tool for the Integration of Neuroimaging Data and the Allen Human Brain Transcriptome Atlas , 2016, PloS one.

[21]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[22]  N. Rosenthal,et al.  Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease , 2014, EMBO molecular medicine.

[23]  A. Uzawa,et al.  Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and Therapeutic Implications , 2014, Brain pathology.

[24]  B. Weinshenker,et al.  Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. , 2013, JAMA neurology.

[25]  Allan R. Jones,et al.  The Allen Human Brain Atlas Comprehensive gene expression mapping of the human brain , 2012, Trends in Neurosciences.

[26]  Allan R. Jones,et al.  An anatomically comprehensive atlas of the adult human brain transcriptome , 2012, Nature.

[27]  M. Battaglini,et al.  Evaluating and reducing the impact of white matter lesions on brain volume measurements , 2012, Human brain mapping.

[28]  Yong He,et al.  A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations , 2012, Multiple sclerosis.

[29]  R. Bergamaschi,et al.  Advanced magnetic resonance imaging of neuromyelitis optica: a multiparametric approach , 2012, Multiple sclerosis.

[30]  S. Pittock,et al.  Paraneoplastic encephalomyelopathies: pathology and mechanisms , 2011, Acta Neuropathologica.

[31]  Uri Laserson,et al.  Autoantigen discovery with a synthetic human peptidome. , 2011, Nature biotechnology.

[32]  John Ashburner,et al.  A fast diffeomorphic image registration algorithm , 2007, NeuroImage.

[33]  A. Bar-Or,et al.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein , 2007, Nature Medicine.

[34]  Daniel Rueckert,et al.  Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data , 2006, NeuroImage.

[35]  B. Weinshenker,et al.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. , 2006, Archives of neurology.

[36]  A. Verkman,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[37]  P. Basser,et al.  Comprehensive approach for correction of motion and distortion in diffusion‐weighted MRI , 2004, Magnetic resonance in medicine.

[38]  P. Shannon,et al.  Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks , 2003 .

[39]  S. Xuan,et al.  Insulin-Like Growth Factor (IGF) Signaling through Type 1 IGF Receptor Plays an Important Role in Remyelination , 2003, The Journal of Neuroscience.

[40]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[41]  Hans Lassmann,et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. , 2002, Brain : a journal of neurology.

[42]  I. Torres-Aleman,et al.  Expression of insulin-like growth factor I by astrocytes in response to injury , 1992, Brain Research.

[43]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[44]  P. Basser,et al.  MR diffusion tensor spectroscopy and imaging. , 1994, Biophysical journal.